Zur Rose Group AG
A European online pharmacy providing pharmaceuticals and digital health services, mainly in Germany.
ROSE | SW
Overview
Corporate Details
- ISIN(s):
- CH0042615283 (+1 more)
- LEI:
- 50670038OH136R5Z4663
- Country:
- Switzerland
- Address:
- Walzmühlestrasse 49, 8500 Frauenfeld
- Sector:
- Wholesale and retail trade
- Industry:
- Retail sale of other goods, except motor vehicles and motorcycles
Description
DocMorris AG, formerly Zur Rose Group AG, is a leading European online pharmacy and digital healthcare company. Its core business revolves around operating e-commerce pharmacies and developing a comprehensive digital healthcare ecosystem. The company's platform aims to connect patients, doctors, pharmacies, and health insurers, facilitating a seamless healthcare experience under its vision, "Health in one click." Following the sale of its Swiss business, DocMorris focuses on its B2C operations, with a primary market in Germany, and also serves customers in the Netherlands, Spain, and France. The company provides a wide range of pharmaceutical products and digital health services, emphasizing high-quality, safe, and low-cost pharmaceutical care.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-16 07:00 |
Earnings Release
DocMorris accelerates sequential Rx growth and increases non-Rx revenue
|
English | 24.2 KB | ||
| 2025-10-16 02:00 |
Earnings Release
DocMorris accelerates sequential Rx growth and increases non-Rx revenue
|
English | 20.5 KB | ||
| 2025-10-16 02:00 |
Earnings Release
DocMorris beschleunigt sequenzielles Rx-Wachstum und steigert Non-Rx-Umsätze
|
German | 21.3 KB | ||
| 2025-09-05 12:55 |
Regulatory News Service
DocMorris safe and certified online supply of medicines
|
English | 5.1 KB | ||
| 2025-08-19 07:00 |
Earnings Release
DocMorris increases Rx revenue by over 40 per cent in the first half of the yea…
|
English | 31.3 KB | ||
| 2025-08-19 02:00 |
Earnings Release
DocMorris increases Rx revenue by over 40 per cent in the first half of the yea…
|
English | 26.0 KB | ||
| 2025-08-19 02:00 |
Earnings Release
DocMorris steigert Rx-Umsatz im ersten Halbjahr um über 40 Prozent und baut Ges…
|
German | 26.6 KB | ||
| 2025-08-19 00:00 |
Interim Report
Half-Year Report 2025
|
English | 194.7 KB | ||
| 2025-07-17 10:31 |
Regulatory News Service
DocMorris launches prescription bonus save up to 15
|
English | 3.8 KB | ||
| 2025-07-17 02:00 |
Legal Proceedings Report
DocMorris AG: Federal Court of Justice confirms admissibility of prescription b…
|
English | 7.8 KB | ||
| 2025-07-17 02:00 |
Legal Proceedings Report
DocMorris AG: BGH bestätigt Zulässigkeit von Rezept-Boni
|
German | 8.2 KB | ||
| 2025-07-15 07:00 |
Regulatory News Service
gematik extends DocMorris CardLink approval until January 2027
|
English | 7.2 KB | ||
| 2025-07-15 02:00 |
Regulatory News Service
gematik extends DocMorris CardLink approval until January 2027
|
English | 5.9 KB | ||
| 2025-07-15 02:00 |
Regulatory News Service
gematik verlängert DocMorris CardLink Zulassung bis Januar 2027
|
German | 6.2 KB | ||
| 2025-06-11 11:18 |
Regulatory News Service
Obesity therapy support programme from DocMorris
|
English | 6.1 KB |
Automate Your Workflow. Get a real-time feed of all Zur Rose Group AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Zur Rose Group AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Zur Rose Group AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-05-20 | N/A | Non-Executive member | Buy | None | 175,188.00 CHF |
| 2025-05-20 | N/A | Non-Executive member | Buy | None | 28,818.00 CHF |
| 2025-05-19 | N/A | Executive member | Buy | None | 34,500.00 CHF |
| 2025-05-19 | N/A | Non-Executive member | Buy | None | 14,040.00 CHF |
| 2025-05-19 | N/A | Executive member | Buy | None | 9,142.50 CHF |
| 2025-05-16 | N/A | Non-Executive member | Buy | None | 1,035,000.00 CHF |
| 2025-05-16 | N/A | Executive member | Buy | None | 46,400.00 CHF |
| 2025-05-16 | N/A | Executive member | Buy | None | 10,315.50 CHF |
| 2025-05-16 | N/A | Non-Executive member | Buy | None | 8,616.00 CHF |
| 2025-05-15 | N/A | Executive member | Buy | None | 678,770.25 CHF |
